Combating Enhanced Intracellular Survival (Eis)-Mediated Kanamycin Resistance of Mycobacterium tuberculosis by Novel Pyrrolo[1,5-a]pyrazine-Based Eis Inhibitors

Atefeh Garzan, Melisa J. Willby, Huy X. Ngo, Chathurada S. Gajadeera, Keith D. Green, Selina Y.L. Holbrook, Caixia Hou, James E. Posey, Oleg V. Tsodikov, Sylvie Garneau-Tsodikova

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Tuberculosis (TB) remains one of the leading causes of mortality worldwide. Hence, the identification of highly effective antitubercular drugs with novel modes of action is crucial. In this paper, we report the discovery and development of pyrrolo[1,5-a]pyrazine-based analogues as highly potent inhibitors of the Mycobacterium tuberculosis (Mtb) acetyltransferase enhanced intracellular survival (Eis), whose up-regulation causes clinically observed resistance to the aminoglycoside (AG) antibiotic kanamycin A (KAN). We performed a structure-activity relationship (SAR) study to optimize these compounds as potent Eis inhibitors both against purified enzyme and in mycobacterial cells. A crystal structure of Eis in complex with one of the most potent inhibitors reveals that the compound is bound to Eis in the AG binding pocket, serving as the structural basis for the SAR. These Eis inhibitors have no observed cytotoxicity to mammalian cells and are promising leads for the development of innovative AG adjuvant therapies against drug-resistant TB.

Original languageEnglish
Pages (from-to)302-309
Number of pages8
JournalACS Infectious Diseases
Volume3
Issue number4
DOIs
StatePublished - Apr 14 2017

Bibliographical note

Publisher Copyright:
© 2017 American Chemical Society.

Keywords

  • aminoglycoside acetyltransferase
  • bacterial resistance
  • drug combination
  • enzyme inactivation
  • structure-activity-relationship analysis

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Combating Enhanced Intracellular Survival (Eis)-Mediated Kanamycin Resistance of Mycobacterium tuberculosis by Novel Pyrrolo[1,5-a]pyrazine-Based Eis Inhibitors'. Together they form a unique fingerprint.

Cite this